Specific PIK3 inhibitors are being employed in clinical trials of advanced stage cancers, and the positive overall response rates and progression-free survival rates being observed for PIK3CA-mutant tumors may make this a useful therapeutic strategy for a subset of craniopharygiomas [35, 36]. Here, PIK3CG is linked to cancer.